ATE547097T1 - Zonisamid-formulierung mit verzögerter freisetzung - Google Patents

Zonisamid-formulierung mit verzögerter freisetzung

Info

Publication number
ATE547097T1
ATE547097T1 AT06838427T AT06838427T ATE547097T1 AT E547097 T1 ATE547097 T1 AT E547097T1 AT 06838427 T AT06838427 T AT 06838427T AT 06838427 T AT06838427 T AT 06838427T AT E547097 T1 ATE547097 T1 AT E547097T1
Authority
AT
Austria
Prior art keywords
sustained release
release zonisamide
zonisamide formulation
formulation
sustained
Prior art date
Application number
AT06838427T
Other languages
English (en)
Inventor
Anthony A Mckinney
Gary Tollefson
Simon Yau
Ron Vladyka
Rick Soltero
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Application granted granted Critical
Publication of ATE547097T1 publication Critical patent/ATE547097T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06838427T 2005-11-28 2006-11-27 Zonisamid-formulierung mit verzögerter freisetzung ATE547097T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74003405P 2005-11-28 2005-11-28
US83211006P 2006-07-19 2006-07-19
US83556406P 2006-08-04 2006-08-04
PCT/US2006/045445 WO2007062228A1 (en) 2005-11-28 2006-11-27 Sustained-release formulation of zonisamide

Publications (1)

Publication Number Publication Date
ATE547097T1 true ATE547097T1 (de) 2012-03-15

Family

ID=37898367

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06838427T ATE547097T1 (de) 2005-11-28 2006-11-27 Zonisamid-formulierung mit verzögerter freisetzung

Country Status (12)

Country Link
US (3) US20070148237A1 (de)
EP (1) EP1954241B1 (de)
JP (4) JP2009517394A (de)
AR (1) AR057946A1 (de)
AT (1) ATE547097T1 (de)
CY (1) CY1112791T1 (de)
DK (1) DK1954241T3 (de)
ES (1) ES2383330T3 (de)
PL (1) PL1954241T3 (de)
PT (1) PT1954241E (de)
TW (1) TWI425944B (de)
WO (1) WO2007062228A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2350327C2 (ru) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
EP1951212A2 (de) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TW201811315A (zh) * 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2303025A4 (de) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Verfahren zur behandlung von eingeweidefettbeschwerden
CA2722093C (en) * 2008-05-30 2015-04-28 Ucb Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
AU2009316876A1 (en) * 2008-11-20 2011-07-07 Avantor Performance Materials, Inc. Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient
DE102009035649A1 (de) * 2009-07-29 2011-02-03 Siemens Aktiengesellschaft Arzneistoff und Verfahren zur Erprobung eines Arzneistoffes
EP3659604A1 (de) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
CA2879603A1 (en) * 2012-07-27 2014-01-30 Ratiopharm Gmbh Oral dosage forms for modified release comprising ruxolitinib
NZ745921A (en) * 2016-03-09 2021-12-24 Nls 1 Pharma Ag A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
WO2017213208A1 (ja) * 2016-06-09 2017-12-14 Ｄｓファーマアニマルヘルス株式会社 動物用徐放性製剤組成物
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
AU2020257406A1 (en) * 2019-04-19 2021-12-16 Hoffman Technologies Llc Sustained release formulations
WO2021053542A1 (en) * 2019-09-20 2021-03-25 Dr. Reddy’S Laboratories Limited Pharmaceutical compositions for obesity management
CN114344271B (zh) * 2022-01-18 2022-08-30 深圳市资福药业有限公司 一种唑尼沙胺片的制备方法
EP4593814A1 (de) 2022-09-26 2025-08-06 Rose Research Center, LLC Kombination zur verwendung in einem verfahren zur verhinderung von gewichtszunahme
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
WO1999007342A1 (en) * 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6652882B1 (en) * 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6797283B1 (en) * 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US20030035840A1 (en) * 2001-02-08 2003-02-20 Boyong Li Controlled release oral dosage form
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6489350B1 (en) * 1999-09-15 2002-12-03 Elan Pharmaceuticals, Inc. Methods for treating neuropathic pain using heteroarylmethanesulfonamides
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6960357B2 (en) * 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
JP4545584B2 (ja) * 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
CA2492488A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
ES2355723T3 (es) * 2002-09-11 2011-03-30 Elan Pharma International Limited Composiciones de agente activo en nanopartículas estabilizadas en gel.
AU2003283958A1 (en) * 2002-09-13 2004-04-30 Elan Pharmaceuticals, Inc. Method of treating tremors
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20040158194A1 (en) * 2003-02-06 2004-08-12 Wolff Andy And Beiski Ben Z. Oral devices and methods for controlled drug release
WO2004087175A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
EP1633400A2 (de) * 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutische kombinationen von atypischen antipsychotika mit gaba-modulatoren, anticonvulsiva oder benzodiazepinen
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20050019385A1 (en) * 2003-07-21 2005-01-27 Noven Pharmaceuticals, Inc. Composition and method for controlling drug delivery from silicone adhesive blends
ES2318330T3 (es) * 2003-08-08 2009-05-01 Elan Pharma International Limited Nuevas composiciones de metaxalona.
RS51934B (sr) * 2003-08-08 2012-02-29 Biovail Laboratories International Srl. Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
US20050181049A1 (en) * 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
SE0400378D0 (sv) * 2004-02-17 2004-02-17 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug

Also Published As

Publication number Publication date
WO2007062228A1 (en) 2007-05-31
TW200806289A (en) 2008-02-01
US20070148237A1 (en) 2007-06-28
PL1954241T3 (pl) 2013-03-29
JP6169411B2 (ja) 2017-07-26
JP2009517394A (ja) 2009-04-30
PT1954241E (pt) 2012-06-01
AR057946A1 (es) 2007-12-26
EP1954241B1 (de) 2012-02-29
EP1954241A1 (de) 2008-08-13
TWI425944B (zh) 2014-02-11
CY1112791T1 (el) 2016-02-10
ES2383330T3 (es) 2012-06-20
JP2017082013A (ja) 2017-05-18
JP2016011308A (ja) 2016-01-21
JP2013147513A (ja) 2013-08-01
DK1954241T3 (da) 2012-06-18
US20160354348A1 (en) 2016-12-08
US20140080857A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
FR22C1008I2 (fr) Composition immunogène
ITMI20050728A1 (it) Formulazione innovativa
ATE547097T1 (de) Zonisamid-formulierung mit verzögerter freisetzung
ATE551989T1 (de) Kleinmolekülige heilmittelformulierung mit verzögerter freisetzung
ATE443753T1 (de) Nuancierungsmittel
NO20082563L (no) HCV prodroge formulering
AR062844A1 (es) Composicion pesticida
DE602006000913D1 (de) Tensidzusammensetzung
DK1978944T3 (da) Blød-gelatine-kapselformulering
NO20055686D0 (no) Sammensetning
DE602006012066D1 (de) Daraus
EP1893244A4 (de) Kontrastmittel
ITPD20060384A1 (it) Dispositivo di manipolazione
EE200800057A (et) Antimikroobne ravimvorm
EP1847264A4 (de) Pflaster
FR2881947B1 (fr) Orthese reversible
DE602006007836D1 (de) Kontrastmittel
ITPD20050018A1 (it) Composizione insetticida
DE502006002564D1 (de) Ndungen
DE502006002822D1 (de) Ges
DK1855661T3 (da) Aviptadilformulering
AT502106A3 (de) Gegenstände
FR2882621B1 (fr) Andaineuse reversible
ITMN20050062A1 (it) Dispositivo di gioco
ITMI20050356U1 (it) Dispositivo di gioco